It has been shown that patients harboring EGFR exon 19 deletion mutation respond better not only to EGFR‐TKIs but also to platinum‐based chemotherapy than patients with EGFR L858R mutation, but the underlying mechanism remains elusive.19, 20 With regard to our results, we suspected that downregulation of ERCC1 by EGFR exon 19 deletion signals impaired DNA damage repair ability could be the reason to explain that NSCLC with EGFR exon 19 deletion showed better response to platinum as compared with EGFR L858R mutation. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.